These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 32914727)

  • 1. Berberine as a Potential Multi-Target Agent for Metabolic Diseases: A Review of Investigations for Berberine.
    Wang S; Xu Z; Cai B; Chen Q
    Endocr Metab Immune Disord Drug Targets; 2021; 21(6):971-979. PubMed ID: 32914727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Berberine in the treatment of metabolism-related chronic diseases: A drug cloud (dCloud) effect to target multifactorial disorders.
    Kong WJ; Vernieri C; Foiani M; Jiang JD
    Pharmacol Ther; 2020 May; 209():107496. PubMed ID: 32001311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic effect of berberine on metabolic diseases: Both pharmacological data and clinical evidence.
    Xu X; Yi H; Wu J; Kuang T; Zhang J; Li Q; Du H; Xu T; Jiang G; Fan G
    Biomed Pharmacother; 2021 Jan; 133():110984. PubMed ID: 33186794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect and mechanism of berberine against polycystic ovary syndrome.
    Zhang SW; Zhou J; Gober HJ; Leung WT; Wang L
    Biomed Pharmacother; 2021 Jun; 138():111468. PubMed ID: 33740526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Berberine in Cardiovascular and Metabolic Diseases: From Mechanisms to Therapeutics.
    Feng X; Sureda A; Jafari S; Memariani Z; Tewari D; Annunziata G; Barrea L; Hassan STS; Šmejkal K; Malaník M; Sychrová A; Barreca D; Ziberna L; Mahomoodally MF; Zengin G; Xu S; Nabavi SM; Shen AZ
    Theranostics; 2019; 9(7):1923-1951. PubMed ID: 31037148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxyberberine, an absorbed metabolite of berberine, possess superior hypoglycemic effect via regulating the PI3K/Akt and Nrf2 signaling pathways.
    Dou Y; Huang R; Li Q; Liu Y; Li Y; Chen H; Ai G; Xie J; Zeng H; Chen J; Luo C; Su Z
    Biomed Pharmacother; 2021 May; 137():111312. PubMed ID: 33524788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Mechanistic Review on How Berberine Use Combats Diabetes and Related Complications: Molecular, Cellular, and Metabolic Effects.
    Askari VR; Khosravi K; Baradaran Rahimi V; Garzoli S
    Pharmaceuticals (Basel); 2023 Dec; 17(1):. PubMed ID: 38275993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Berberine alleviates type 2 diabetic symptoms by altering gut microbiota and reducing aromatic amino acids.
    Yao Y; Chen H; Yan L; Wang W; Wang D
    Biomed Pharmacother; 2020 Nov; 131():110669. PubMed ID: 32937246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Berberine Ameliorates Metabolic-Associated Fatty Liver Disease Mediated Metabolism Disorder and Redox Homeostasis by Upregulating Clock Genes: Clock and Bmal1 Expressions.
    Ye C; Zhang Y; Lin S; Chen Y; Wang Z; Feng H; Fang G; Quan S
    Molecules; 2023 Feb; 28(4):. PubMed ID: 36838862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Berberine action targets and its absorption behavior：how to use old drug for new mechanisms].
    Yuan ZY; Wang YG; Chai YS; Hu J; Jiang JF; Yan XJ; Du LJ
    Zhongguo Zhong Yao Za Zhi; 2016 Jun; 41(12):2362-2370. PubMed ID: 28901086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Berberine alleviates insulin resistance by reducing peripheral branched-chain amino acids.
    Yue SJ; Liu J; Wang AT; Meng XT; Yang ZR; Peng C; Guan HS; Wang CY; Yan D
    Am J Physiol Endocrinol Metab; 2019 Jan; 316(1):E73-E85. PubMed ID: 30422704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Micro- and Nanoencapsulated Hybrid Delivery System (MNEHDS): A Novel Approach for Colon-Targeted Oral Delivery of Berberine.
    Zhang L; Li M; Zhang G; Gao C; Wang S; Zhang T; Ma C; Wang L; Zhu Q
    Mol Pharm; 2021 Apr; 18(4):1573-1581. PubMed ID: 33629860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Berberine improves glucogenesis and lipid metabolism in nonalcoholic fatty liver disease.
    Zhao L; Cang Z; Sun H; Nie X; Wang N; Lu Y
    BMC Endocr Disord; 2017 Feb; 17(1):13. PubMed ID: 28241817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Berberine-induced bioactive metabolites of the gut microbiota improve energy metabolism.
    Wang Y; Shou JW; Li XY; Zhao ZX; Fu J; He CY; Feng R; Ma C; Wen BY; Guo F; Yang XY; Han YX; Wang LL; Tong Q; You XF; Lin Y; Kong WJ; Si SY; Jiang JD
    Metabolism; 2017 May; 70():72-84. PubMed ID: 28403947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Berberine hydrochloride protects against cytokine-induced inflammation through multiple pathways in undifferentiated C2C12 myoblast cells.
    Poudel A; Zhou JY; Mekala N; Welchko R; Rosca MG; Li L
    Can J Physiol Pharmacol; 2019 Aug; 97(8):699-707. PubMed ID: 31026403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Berberine Modulates Gut Microbiota and Reduces Insulin Resistance via the TLR4 Signaling Pathway.
    Liu D; Zhang Y; Liu Y; Hou L; Li S; Tian H; Zhao T
    Exp Clin Endocrinol Diabetes; 2018 Sep; 126(8):513-520. PubMed ID: 29365334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Effects of Berberine on Liver Fibrosis are associated With Lipid Metabolism and Intestinal Flora.
    Liu X; Wang L; Tan S; Chen Z; Wu B; Wu X
    Front Pharmacol; 2022; 13():814871. PubMed ID: 35308208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Berberine ameliorates ovariectomy-induced anxiety-like behaviors by enrichment in equol generating gut microbiota.
    Fang Y; Zhang J; Zhu S; He M; Ma S; Jia Q; Sun Q; Song L; Wang Y; Duan L
    Pharmacol Res; 2021 Mar; 165():105439. PubMed ID: 33493658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Orally Administered Berberine Modulates Hepatic Lipid Metabolism by Altering Microbial Bile Acid Metabolism and the Intestinal FXR Signaling Pathway.
    Sun R; Yang N; Kong B; Cao B; Feng D; Yu X; Ge C; Huang J; Shen J; Wang P; Feng S; Fei F; Guo J; He J; Aa N; Chen Q; Pan Y; Schumacher JD; Yang CS; Guo GL; Aa J; Wang G
    Mol Pharmacol; 2017 Feb; 91(2):110-122. PubMed ID: 27932556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Berberine is a potential therapeutic agent for metabolic syndrome via brown adipose tissue activation and metabolism regulation.
    Hu X; Zhang Y; Xue Y; Zhang Z; Wang J
    Am J Transl Res; 2018; 10(11):3322-3329. PubMed ID: 30662589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.